AVROBIO to Present New Clinical and Preclinical Data Across Multiple Programs at the ESGCT 28th Annual Congress
New safety data to be reported from clinical trials in Fabry disease and Gaucher disease type 1
Clinical and preclinical data from across the company’s pipeline of lysosomal disorder gene therapy programs will be included in two oral presentations and five poster presentations. Additionally,
The presentations are listed below, and the full program is available online at the ESGCT website.
ORAL PRESENTATIONS:
“High-resolution cellular and molecular follow-up of lysosomal disorder patients treated with hematopoietic stem cell lentiviral gene therapy”
“AVR-RD-01, an investigational lentiviral gene therapy for Fabry disease: interim results from Phase 1 and Phase 2 studies”
RECORDED POSTER PRESENTATIONS:
“Safety profile of conditioning regimens of AVROBIO’s investigational ex vivo lentiviral gene therapy for Fabry disease”
“The GUARD1 clinical trial: A first in-human, open-label, multinational phase 1/2 study of AVR-RD-02 ex-vivo lentiviral vector, autologous gene therapy for Gaucher disease”
“High throughput characterization of CD34+ cell states and dynamics upon genetic engineering”
Cristina Baricordi, Ph.D., senior scientist,
“Transplantation of gene-modified hematopoietic stem cells address disfunction in the periphery and the brain of murine models of neurodegenerative disease”
“Sustained, long-term, correction of neuropathology in a mouse model of Hunter disease following stem cell gene therapy with an LV.IDS.ApoEII vector”
About
Our vision is to bring personalized gene therapy to the world. We aim to prevent, halt or reverse disease throughout the body with a single dose of gene therapy designed to drive durable expression of therapeutic protein, even in hard-to-reach tissues and organs including brain, muscle and bone. Our ex vivo lentiviral gene therapy pipeline includes clinical programs in Fabry disease, Gaucher disease type 1 and cystinosis, as well as preclinical programs in Hunter syndrome, Gaucher disease type 3 and Pompe disease.
Forward-Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “aims,” “anticipates,” “believes,” “could,” “designed to,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words and phrases or similar expressions that are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding our business strategy for and the potential therapeutic benefits of our product candidates, the design, commencement, enrollment and timing of ongoing or planned clinical trials, clinical trial results, product approvals and regulatory pathways, anticipated benefits of our gene therapy platform including potential impact on our commercialization activities, timing and likelihood of success, the expected benefits and results of our implementation of the plato platform in our clinical trials and gene therapy programs, and the expected safety profile of our investigational gene therapies. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Results in preclinical or early-stage clinical trials may not be indicative of results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented.
Any forward-looking statements in this press release are based on AVROBIO’s current expectations, estimates and projections about our industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of AVROBIO’s product candidates will not be successfully developed or commercialized, the risk of cessation or delay of any ongoing or planned clinical trials of
View source version on businesswire.com: https://www.businesswire.com/news/home/20211006005287/en/
Investors:
Westwicke, an
339-970-2843
chris.brinzey@westwicke.com
Media:
Ten
617-999-9620
krodophele@tenbridgecommunications.com
Source: